Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Increase in Short Interest

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 1,588,400 shares, an increase of 28.4% from the January 15th total of 1,237,500 shares. Based on an average daily trading volume, of 2,000 shares, the days-to-cover ratio is currently 794.2 days.

Wall Street Analyst Weigh In

ZLDPF has been the subject of a number of recent research reports. Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, January 21st. JPMorgan Chase & Co. began coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an "overweight" rating for the company.

Zealand Pharma A/S Trading Up 0.1 %

Shares of OTCMKTS:ZLDPF traded up $0.11 during midday trading on Monday, hitting $104.01. The company had a trading volume of 250 shares, compared to its average volume of 756. Zealand Pharma A/S has a 12 month low of $67.58 and a 12 month high of $141.74. The company has a current ratio of 35.49, a quick ratio of 35.49 and a debt-to-equity ratio of 0.03. The stock has a market cap of $7.39 billion, a price-to-earnings ratio of -42.80 and a beta of 0.88. The firm has a fifty day simple moving average of $102.14 and a 200 day simple moving average of $114.10.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.